Evidence map›Paper›PMID 41376640›Full record

ArticleFrontiers in immunology2025

Harnessing mRNA technology against

Javier Sánchez-Montejo, Cristina Teodosio, Tania Strilets, Julio López-Abán, Raúl Manzano-Román, Julio Pozo, Silvia Martin, Lidia Silos, Ignacio Trujillo, Mariano A García-Blanco and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Javier Sánchez-MontejoInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca, Research Centre for Tropical Diseases at the University of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) - Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.
Cristina TeodosioCancer Research Center Instituto Universitario de Biología Molecular y Celular del Cancer, Universidad de Salamanca - Consejo Superior de Investigaciones Científicas (IBMCC, USAL-CSIC), Salamanca, Spain.
Tania StriletsDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, United States.
Julio López-AbánInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca, Research Centre for Tropical Diseases at the University of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) - Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.
Raúl Manzano-RománInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca, Research Centre for Tropical Diseases at the University of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) - Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.
Julio PozoCytometry Service (NUCLEUS), University of Salamanca (USAL), Salamanca, Spain.
Silvia MartinCytometry Service (NUCLEUS), University of Salamanca (USAL), Salamanca, Spain.
Lidia SilosBiomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Ignacio TrujilloInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca, Research Centre for Tropical Diseases at the University of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) - Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.
Mariano A García-BlancoDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, United States.
Belén VicenteInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca, Research Centre for Tropical Diseases at the University of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) - Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.
Antonio MuroInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca, Research Centre for Tropical Diseases at the University of Salamanca Instituto de Investigación Biomédica de Salamanca (IBSAL) - Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mRNA platforms offer a promising strategy to overcome limitations in helminth vaccinology. We used the helminth

Indexed as

Fasciola hepaticaFascioliasisFatty Acid-Binding ProteinsHelminth ProteinsRNA, MessengerVaccinesAnimalsAntibodies, HelminthAntigens, HelminthFemaleHEK293 CellsHumansMiceMice, Inbred BALB CAntibodies, HelminthAntigens, HelminthFatty Acid-Binding ProteinsHelminth ProteinsRNA, MessengerVaccinescytometryFABPFasciola hepaticamRNA vaccineparasitetrematode

Identifiers

PMID41376640
PMCPMC12687294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.